Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and Drug Administration.

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Patients who bought stockpiles of alternative GLP-1 drugs online aren't sure what to do with them after learning that the ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Zepbound (tirzepatide) is only available on ... found both methods of drug administration easy to manage. Eli Lilly also states that vial forms are cheaper than the auto-injector pre-filled ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price target of $950.00. David Risinger has given his Buy rating ...

To address this, American pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven effective in managing both obesity and type-2 diabetes.

This indicates there remains much potential in the molecules used as the basis for obesity drugs -- semaglutide for Novo Nordisk, and tirzepatide in the case of Eli Lilly. Waxing bullish about the ...

Eli Lilly and Novo Nordisk ... The telehealth company Ro, which in the past offered compounded tirzepatide, in December announced it would be offering single-dose vials of Zepbound to patients with ...